source
- Epkinly shows 51% PFS boost in frontline DLBCL, may become new standard of careAbbVie and Genmab reported that their bispecific antibody Epkinly achieved a substantial gain in progression‑free survival when added to the standard R‑CHOP regimen in newly diagnosed diffuse large…
- Compliance worries keep AI adoption in drug manufacturing low, survey findsA new survey of more than 400 research and manufacturing professionals shows that over 90% of drugmakers have not committed to expanding AI use in regulated drug production. While AI is widely em…